QQ客服 官方微博 反馈留言

	Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
	Li, K.; Wang, J.; Han, B.; Zhao, Y.; Wang, Q.; Zhang, L.; Shi, J.; Wang, Z.; He, J.; Shi, Y.
	2017
卷号	12期号:11页码:S2236-S2236
关键词	NSCLC Anlotinib third-line treatment
ISSN号	1556-0864
DOI	10.1016/j.jtho.2017.09.1528
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6369534
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li, K.,Wang, J.,Han, B.,et al. Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303[J],2017,12(11):S2236-S2236.
APA	Li, K..,Wang, J..,Han, B..,Zhao, Y..,Wang, Q..,...&Wang, H..(2017).Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303.,12(11),S2236-S2236.
MLA	Li, K.,et al."Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303".12.11(2017):S2236-S2236.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。